The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2019 Nov 28

PMID 31771261

Citations 46

Authors

Kurt Sartorius

Julia Makarova

Benn Sartorius

Ping An

Cheryl Winkler

Anil Chuturgoon

Anna Kramvis

Affiliations

Soon will be listed here.

Abstract

The incidence and mortality of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HBV-HCC) is an intractable public health problem in developing countries that is compounded by limited early detection and therapeutic options. Despite the early promise of utilizing the regulatory role of miRNA in liver cancer, this field remains largely in the work-in-progress phase. This exploratory review paper adopts a broad focus in order to collate evidence of the regulatory role of miRNA in each stage of the HBV-HCC continuum. This includes the regulatory role of miRNA in early HBV infection, chronic inflammation, fibrosis/cirrhosis, and the onset of HCC. The paper specifically investigates HBV dysregulated miRNA that influence the expression of the host/HBV genome in HBV-HCC pathogenesis and fully acknowledges that this does not cover the full spectrum of dysregulated miRNA. The sheer number of dysregulated miRNA in each phase support a hypothesis that future therapeutic interventions will need to consider incorporating multiple miRNA panels.

Citing Articles

The interactive role of microRNA and other non-coding RNA in hepatitis B (HBV) associated fibrogenesis.

Sartorius K, Wang Y, Sartorius B, Antwi S, Li X, Chuturgoon A Funct Integr Genomics. 2025; 25(1):24.

PMID: 39847120 DOI: 10.1007/s10142-024-01519-4.

MicroRNA-3145 as a potential therapeutic target for hepatitis B virus: inhibition of viral replication via downregulation of HBS and HBX.

Muchtar A, Onomura D, Ding D, Nishitsuji H, Shimotohno K, Okada S Front Microbiol. 2025; 15:1499216.

PMID: 39834379 PMC: 11743939. DOI: 10.3389/fmicb.2024.1499216.

State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment.

Giron-Michel J, Padelli M, Oberlin E, Guenou H, Duclos-Vallee J BioDrugs. 2025; 39(2):237-260.

PMID: 39826071 PMC: 11906529. DOI: 10.1007/s40259-024-00702-0.

MicroRNA levels in patients with chronic hepatitis B virus and HIV coinfection in a high-prevalence setting; KwaZulu-Natal, South Africa.

Mthethwa L, Parboosing R, Msomi N BMC Infect Dis. 2024; 24(1):833.

PMID: 39148016 PMC: 11328411. DOI: 10.1186/s12879-024-09715-0.

Current updates on the molecular and genetic signals as diagnostic and therapeutic targets for hepatitis B virus-associated hepatic malignancy.

Adugna A, Muche Y, Melkamu A, Jemal M, Belew H, Amare G Heliyon. 2024; 10(14):e34288.

PMID: 39100497 PMC: 11295980. DOI: 10.1016/j.heliyon.2024.e34288.

References

Kan F, Ye L, Yan T, Cao J, Zheng J, Li W . Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model. BMC Genomics. 2017; 18(1):641. PMC: 5568174. DOI: 10.1186/s12864-017-3984-z. View

Brechot C . Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004; 127(5 Suppl 1):S56-61. DOI: 10.1053/j.gastro.2004.09.016. View

Xie Y, Yao Q, Butt A, Guo J, Tian Z, Bao X . Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther. 2014; 15(9):1248-55. PMC: 4128867. DOI: 10.4161/cbt.29688. View

Zhou W, Zhang Q, Qiao L . Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014; 20(23):7312-24. PMC: 4064077. DOI: 10.3748/wjg.v20.i23.7312. View

Zou C, Li Y, Cao Y, Zhang J, Jiang J, Sheng Y . Up-regulated MicroRNA-181a induces carcinogenesis in hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. BMC Cancer. 2014; 14:97. PMC: 3930291. DOI: 10.1186/1471-2407-14-97. View

Jiang X, Kanda T, Wu S, Nakamura M, Miyamura T, Nakamoto S . Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity. World J Gastroenterol. 2014; 20(23):7197-206. PMC: 4064064. DOI: 10.3748/wjg.v20.i23.7197. View

Murakami Y, Kawada N . MicroRNAs in hepatic pathophysiology. Hepatol Res. 2016; 47(1):60-69. DOI: 10.1111/hepr.12730. View

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi Y . MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol. 2012; 41(3):869-75. PMC: 3582905. DOI: 10.3892/ijo.2012.1535. View

10.

Feng G, Li J, Yang Z, Zhang S, Liu Y, Zhang W . Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA. Oncogene. 2017; 36(50):6895-6905. DOI: 10.1038/onc.2017.291. View

11.

Cui M, Wang Y, Sun B, Xiao Z, Ye L, Zhang X . MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem Biophys Res Commun. 2014; 444(2):270-5. DOI: 10.1016/j.bbrc.2014.01.051. View

12.

Ma R, Jiang T, Kang X . Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 2012; 31:38. PMC: 3431991. DOI: 10.1186/1756-9966-31-38. View

13.

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

14.

Whittaker S, Marais R, Zhu A . The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29(36):4989-5005. DOI: 10.1038/onc.2010.236. View

15.

Callegari E, Gramantieri L, Domenicali M, DAbundo L, Sabbioni S, Negrini M . MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2014; 22(1):46-57. PMC: 4262781. DOI: 10.1038/cdd.2014.136. View

16.

Tacke F, Luedde T, Trautwein C . Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol. 2008; 36(1):4-12. DOI: 10.1007/s12016-008-8091-0. View

17.

Cheng J, Zhao H, Yang S, Chen E, Chen W, Li L . Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT. Hepatol Int. 2018; 12(3):277-287. DOI: 10.1007/s12072-018-9871-0. View

18.

Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy P, Lampertico P . Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007; 204(3):667-80. PMC: 2137916. DOI: 10.1084/jem.20061287. View

19.

Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S . MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009; 69(14):5761-7. DOI: 10.1158/0008-5472.CAN-08-4797. View

20.

Hermeking H . The miR-34 family in cancer and apoptosis. Cell Death Differ. 2009; 17(2):193-9. DOI: 10.1038/cdd.2009.56. View